Analyst Upgrades Keep LRMR Shares Flat Despite Drug Safety Concerns
LRMR•LRMR shares remained flat on July 2 after reports flagged safety concerns with its oncology candidate. Positive analyst notes and upgraded ratings on its clinical pipeline prospects underpinned steady trading, counterbalancing risk sentiment.
1. Market Reaction
LRMR shares closed flat on July 2 after safety concerns emerged around its oncology candidate, reflecting investor caution balanced by bullish sentiment. Trading volume remained near average as market participants assessed the conflicting signals.
2. Analyst Support
Several analysts maintained or raised price targets and reiterated buy ratings, pointing to confidence in the company’s broader pipeline and upcoming data readouts. This positive consensus offset pressure from the safety issues and stabilized the stock’s performance.
